Atty Dkt. No.: UCAL-281

USSN: 10/627,447

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claim 9 without prejudice to renewal.

Please enter the amendments to claims 1, 10, 11, 15, 17, and 18, as shown below.

Please enter new claims 19-22, as shown below.

- 1. (Currently amended) A method for diagnosing Alzheimer's Disease <u>AD</u> in [[an]] <u>a living</u> individual, the method comprising detecting <u>a level of</u> carboxyl-terminal truncated <u>apolipoprotein E</u> (<u>apoE</u>) [[apoE]] in [[a]] <u>an aqueous</u> biological sample from the individual, <u>wherein a level of carboxyl-terminal truncated apoE that is significantly higher than the level present in a normal control indicates that the individual has AD.</u>
 - 2. (Original) The method of claim 1, wherein the biological sample is blood.
 - 3. (Original) The method of claim 1, wherein the biological sample is serum.
- 4. (Original) The method of claim 1, wherein the carboxyl-terminal truncated apoE has a molecular weight of about 14-20 kDa.
- 5. (Original) The method of claim 1, wherein the carboxyl-terminal truncated apoE comprises amino acids 244-260 of apoE.
 - 6. (Original) The method of claim 1, wherein apoE is apoE4.
 - 7. (Original) The method of claim 1, wherein apoE is apoE3.
 - 8. (Original) The method of claim 1, wherein apoE is a mixture of apoE3 and apoE4.
 - 9. (Canceled)

Atty Dkt. No.: UCAL-281

USSN: 10/627,447

10. (Currently amended) The method of claim 1 [[9]], further comprising detecting a level of full length apolipoprotein E (apoE) [[apoE]] in the biological sample from the individual; wherein a ratio of the level of carboxyl-terminal truncated apoE compared to the level of full length apoE in the biological sample that is greater than a ratio associated with a control biological sample from an individual not having Alzheimer's Disease is indicative of a diagnosis of Alzheimer's Disease.

- 11. (Currently amended) The method of claim 10, wherein the carboxyl-terminal truncated apoE [[apoE]] has a molecular weight of about 14-20 kDa.
 - 12. (Original) The method of claim 10, wherein the ratio is greater than about 1.5.
 - 13. (Original) The method of claim 10, wherein the ratio is greater than about 2.
 - 14. (Original) The method of claim 10, wherein the ratio is greater than about 3.
- 15. (Currently amended) A kit for diagnosing Alzheimer's Disease, the kit comprising an antibody that binds to earboxyl-truncated apoE carboxyl-terminal truncated apolipoprotein E (apoE) and instructions for using the antibody for diagnosing Alzheimer's Disease.
 - 16. (Original) The kit of claim 15, further wherein the antibody is attached to a solid support.
- 17. (Currently amended) The kit of claim 15, further comprising an antibody that specifically binds to a carboxyl-terminal portion of <u>full-length</u> apoE.
- 18. (Currently amended) The kit of claim 15, wherein the instructions for the diagnosis of Alzheimer's Disease direct the use of the kit to detect carboxyl-terminal truncated apoE in serum[[.]].
 - 19. (New) The method of claim 1, wherein the biological sample is plasma.
 - 20. (New) The method of claim 1, wherein the biological sample is cerebrospinal fluid.
 - 21. (New) The kit of claim 17, wherein the antibody that specifically binds to a carboxyl-

Atty Dkt. No.: UCAL-281

USSN: 10/627,447

terminal portion of apoE binds specifically to an epitope within amino acids 270-299 of apoE.

22. (New) The kit of claim 16, wherein the solid support is a test strip.